- Home
- WSBC vs DNLI Comparison
WSBC vs DNLI Comparison
Compare WSBC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WSBC | DNLI |
|---|---|---|
| Founded | 1870 | 2013 |
| Country | United States | United States |
| Employees | 2969 | 503 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | WSBC | DNLI |
|---|---|---|
| Price | $36.13 | $19.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $40.50 | $34.27 |
| AVG Volume (30 Days) | 466.4K | ★ 1.8M |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.31 | N/A |
| Revenue Next Year | $7.06 | $444.50 |
| P/E Ratio | $16.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.64 | $12.30 |
| 52 Week High | $38.10 | $23.77 |
Technical Indicators
Market Signals| Indicator | WSBC | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 63.67 | 45.91 |
| Support Level | $35.85 | $18.42 |
| Resistance Level | $37.03 | $20.12 |
| Average True Range (ATR) | 0.71 | 1.21 |
| MACD | 0.37 | -0.07 |
| Stochastic Oscillator | 78.53 | 24.64 |
Price Performance
Historical ComparisonAbout WSBC WesBanco Inc.
Wesbanco Inc is a bank holding company. Through its subsidiaries, it offers a full range of financial services, including retail banking, corporate banking, personal and corporate trust services, brokerage services, mortgage banking, and insurance. WesBanco operates one commercial bank, WesBanco Bank, which runs scores of branches. The company's reportable segments are Community Banking, which derives key revenue, and Trust and Investment Services. The Community Banking segment offers various banking products and services through various delivery channels, including commercial demand, individual demand, and time deposit accounts; commercial, mortgage, and individual installment loans; and certain non-traditional offerings, such as insurance and securities brokerage services.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.